Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems Invests $3M in Genomica, Signs Licensing Agreement

NEW YORK, Sept 6 - Applied Biosystems (NYSE: PEB) said on Wednesday it had agreed to make a $3 million equity investment in software developer Genomica.

The companies also signed an agreement under which Genomica will license its genetic-analysis object model to Applied Biosystems.

The object model will allow Applied Biosystems to store genotyping results garnered from its various instruments in a common Oracle database. Genomica's bioinformatics software products could then be used to access the genotyping results for scientific analysis.

" The object model enhances the capability to pool data,” said Jay Rhodes, a spokesman for Applied Biosystems. “The enhanced Applied Biosystems system is what gets sold.”Rhodes declined to disclose the terms of the licensing agreement or to say what percent of Genomica’s equity Applied Biosystems will own following the deal.

A spokesperson for Genomica was not immediately available for comment.

Based in Foster City, Calif., Applied Biosystems makes instruments, reagents and software used to discover new pharmaceuticals and analyze criminal evidence.

Genomica of Boulder, Colo., develops software products used by pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. The company’s customers include AstraZeneca (NYSE: AZN), GlaxoWellcome (NYSE:GLX), and the National Cancer Institute.

Genomica and Applied Biosystems previously partnered to develop software products to be used with Applied Biosystems’ hardware.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more